Patient and Caregiver Perception of Antibiotics and Antibiotic Resistance in the Context of Managing Acne Vulgaris (AV), and Patient Global Assessment (ptGA) of AV Among Patients Administered Sarecycline in US Clinical Practices: Results from PROSES Study
Main Article Content
Keywords
PROSES, Patient Reported Outcomes, PROs, Caregiver Reported Outcomes, Antibiotics, Antibiotic Resistance, Narrow Spectrum, Sarecycline, Acne, Acne Vulgaris, AV, Patient Global Assessment, ptGA
Abstract
Objectives: To evaluate perceptions about antibiotics and antibiotic resistance among adult patients and caregivers of pediatric patients with AV, and ptGA of AV, in the cohort of AV patients administered sarecycline in community practices across the U.S.
Methods: A single-arm, prospective cohort study (PROSES) was conducted with moderate-to-severe non-nodular AV patients >9 years who were prescribed sarecycline in real-world community practices in the US. At baseline, adult patients and caregivers of pediatric patients with AV were individually asked about their concerns about using (self, or for child, respectively) antibiotics for AV, and the concerns about antibiotic resistance; responses were on a 5-point likert scale of 0 (not at all) to 4 (extremely). ptGA of AV was assessed on a 5-point likert scale of (0 (clear), 1 (almost-clear), 2 (mild), 3 (moderate), 4 (severe)) at baseline and week-12.
Results: A total of 253 AV patients completed the study (adults 60.08%; pediatric 39.92%). Regarding concerns about antibiotics to manage AV, 20.39% of adult AV patients and 31.68% of caregivers (of pediatric AV patients) were somewhat/moderately/extremely concerned; 24.34% and 33.66% of adults and caregivers respectively were slightly concerned, and 55.26% and 34.65% of adults and caregivers respectively were not at all concerned. Regarding concerns about antibiotic resistance, 27.63% and 34.65% of adults and caregivers respectively were somewhat/moderately/extremely concerned; 25.66% and 34.65% of adults and caregivers respectively were slightly concerned, and 46.71% and 30.69% of adults and caregivers respectively were not at all concerned. On ptGA of AV, 59.29% of patients reported clear/almost clear at Wk-12.
Conclusion: Within the study cohort administered sarecycline, a narrow-spectrum, tetracycline-derived antibiotic, adult patients, and caregivers of pediatric patients expressed less concerns about antibiotics or antibiotic resistance at baseline; majority of patients reported clear/almost clear AV after 12 weeks of sarecycline treatment.
References
2. Moore A, et al.Br J Dermatol. 2020;183(2):349-356.
3. Grada A, et al.Antibiotics(Basel). 2022;11(6):722.
4. MacGibeny MA, et al.JAMA Dermatol. 2022;158(9):989-991.
5. Ip A, et al.BMJ Open. 2021;11(2):e041794.
6. Del Rosso JQ, et al. J Clin Aesthet Dermatol.2019;12(6):30-41.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.